Jie Wang, Hui Yuan, Jianan Xu, Chongyi Yang

Department of Urology, Ninghai First Hospital, Zhejiang, People’s Republic of China

Correspondence: Chongyi Yang, Email 460374212@qq.com

Abstract: Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium-177 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC). Many other clinical trials are also in progress in various settings. Both monotherapy and combination studies are underway. However, because of several limitations existed in these clinical trials and alarmed long-term nephrotoxicity of PSMA-targeted therapy, we should be more prudent to this therapy. In this review, we evaluates the evolving clinical and preclinical landscape of PSMA-targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.

Keywords: prostate cancer, prostate-specific membrane antigen, radioligand therapy, lutetium-177, actinium-225